Clinical Trials Sponsored by Iovance Biotherapeutics

Total 582 results

Revolo Biotherapeutics

Completed

Allergen Challenge Trial of IRL201104 in Seasonal Allergic Rhinitis

Seasonal Allergic Rhinitis

United Kingdom
Revolo Biotherapeutics

Completed

Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers

Healthy Volunteer

United Kingdom
Fore Biotherapeutics

Terminated

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Melanoma | Colorectal Cancer | Cholangiocarcinoma | Non-small Cell Lung Cancer | Histiocytosis | Thyroid Cancer | Hairy Cell Leukemia

United States
Gemstone Biotherapeutics

Unknown

Briagen Observational Study (BOS)

Mohs Surgery

United States
Aeglea Biotherapeutics

Completed

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

Arginase I Deficiency | Hyperargininemia

United States, Canada, United Kingdom, Portugal
Atara Biotherapeutics

No longer available

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

CMV Viremia | CMV Disease
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States, Canada
BrightPath Biotherapeutics

Completed

Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma

Melanoma

United States
Pinta Biotherapeutics

Completed

Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting

End Stage Renal Disease | Kidney Disease | Protein Energy Wasting

United States
Fore Biotherapeutics

Completed

NovellusDx Cancer Early Detection Blood Test- Clinical Trial

Lung Cancer

Israel
Northwest Biotherapeutics

Available

Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (DCVax-L EAP)

Glioblastoma Multiforme | GBM

United States
Eleven Biotherapeutics

Completed

A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis (EBI-005-AC-2)

Allergic Conjunctivitis (AC)

United States
Northwest Biotherapeutics

Unknown

Safety and Efficacy Study of DCVax-Direct in Solid Tumors

Melanoma | Colorectal Cancer | Pancreatic Cancer | Liver Cancer | Locally Advanced Tumor | Metastatic Solid Tissue Tumors

United States
Jennerex Biotherapeutics

Completed

A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib (TRAVERSE)

HCC | Hepatocellular Carcinoma | Liver Cancer

Korea, Republic of, United States, Hong Kong, Canada, Germany, France, Taiwan
Jennerex Biotherapeutics

Completed

A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma

Melanoma

United States
Atara Biotherapeutics

Not yet recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis

Systemic Lupus Erythematosus | Lupus Nephritis
Fore Biotherapeutics

Recruiting

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Volunteers.

Healthy Volunteer

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

High-grade B-cell Lymphoma | MCL | Diffuse Large B-cell Lymphoma (DLBCL) | Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | DLBCL/High-grade B-cell Lymphoma With MYC and BCL2 Rearrangements | Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma | LBCL With IRF4 Rearrangement | High-grade B-cell... and other conditions

United States
Alethia Biotherapeutics

Recruiting

Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis (EGIA-003)

Metastatic Colorectal Cancer

Canada
Tavotek Biotherapeutics

Recruiting

A Study of TAVO101 in Atopic Dermatitis Patients

Atopic Dermatitis

New Zealand
Aro Biotherapeutics

Recruiting

Study to Assess the Safety, Tolerability, PK and PD of ABX1100

Healthy

Canada
Latigo Biotherapeutics

Recruiting

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

Healthy

New Zealand
Barinthus Biotherapeutics

Completed

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

HPV Infection | CIN1

Belgium, United Kingdom, Estonia
BrightPath Biotherapeutics

Terminated

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

Metastatic NSCLC

United States
Northwest Biotherapeutics

Active, not recruiting

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (GBM)

Glioma | Glioblastoma | Brain Cancer | Brain Tumor | Glioblastoma Multiforme | GBM | Grade IV Astrocytoma

United States, Germany, Canada, United Kingdom
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Advanced Cancers

United States
Alethia Biotherapeutics

Completed

Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy

Solid Tumor | Metastatic Cancer

Canada
Eleven Biotherapeutics

Completed

Phase 3 Study of EBI-005 in Dry Eye Disease (EBI-005)

Dry Eye Disease (DED)

United States
Eleven Biotherapeutics

Completed

A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)

Allergic Conjunctivitis

Canada
Eleven Biotherapeutics

Completed

A Multi-Center Study Subjects With Dry Eye Syndrome (EBI)

Dry Eye Syndrome

United States
Eleven Biotherapeutics

Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects (EBI-005-1)

Dry Eye

United States
Northwest Biotherapeutics

Withdrawn

Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.

Prostate Cancer

United States
Jennerex Biotherapeutics

Terminated

Neoadjuvant Study of Recombinant Vaccinia Virus to Treat Metastatic Colorectal Carcinoma in Patients Undergoing Complete Resection of Liver Tumors

Colorectal Carcinoma

Canada
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb; Iovance Biotherapeutics, Inc.; Prometheus Inc.

Completed

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Skin Cancer | Melanoma (Skin)

United States
NeoTherapeutics

Completed

Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

Peripheral Nervous System Diseases | Chemotherapy-Induced Peripheral Neuropathy

United States
Claris Biotherapeutics, Inc.

Recruiting

Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars

Corneal Scar

United States
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
Bridge Biotherapeutics, Inc.

Recruiting

First-in-Human Study of BBT-207 in Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation After Treatment With EGFR TKI

EGFR Mutant Advanced Non-Small Cell Lung Cancer

Korea, Republic of, United States
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-020 Injection in Subjects With Advanced Malignant Tumors.

Advanced Malignant Tumors

China
Immorna Biotherapeutics, Inc.

Recruiting

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

Malignant Solid Tumor | Cutaneous Tumor

China
Salubris Biotherapeutics Inc

Recruiting

Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Melanoma | Clear Cell Renal Cell Carcinoma | Cancer | Hepatocellular Carcinoma | Colorectal Cancer | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Advanced Solid Tumor | Epithelial Ovarian Cancer | Non-small Cell... and other conditions

Belgium, Spain
TILT Biotherapeutics Ltd.

Recruiting

TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy (TUNIMO)

Solid Tumor

Finland
Oxford BioTherapeutics Ltd

Recruiting

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

Solid Tumor

United States, Belgium, Spain, France, Greece
Stealth BioTherapeutics Inc.

Completed

A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome (TAZPOWER)

Barth Syndrome

United States
Arcutis Biotherapeutics, Inc.

Completed

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema

Chronic Hand Eczema

United States, Australia, Canada
TILT Biotherapeutics Ltd.

Active, not recruiting

TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL)

Metastatic Melanoma

France, Denmark
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
Arcutis Biotherapeutics, Inc.

Active, not recruiting

Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE)

Atopic Dermatitis Eczema

United States, Canada
Conjupro Biotherapeutics, Inc.

Suspended

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

CD20 Positive Non Hodgkin Lymphoma

United States

Clinical Trials Sponsored by Iovance Biotherapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations